Works matching IS 13657852 AND DT 2012 AND VI 15 AND IP 3

Results: 16

Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 213, doi. 10.1038/pcan.2011.64

By:

Gueron, G;
De Siervi, A;
Vazquez, E

Publication type:

Article

Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 289, doi. 10.1038/pcan.2012.7

By:

Kamrava, M;
Kesarwala, A H;
Madan, R A;
Lita, E;
Kaushal, A;
Tsang, K-Y;
Poole, D J;
Steinberg, S M;
Ferrara, T;
Dahut, W;
Schlom, J;
Gulley, J L

Publication type:

Article

Role of 5α-reductase inhibitors in benign prostatic diseases.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 222, doi. 10.1038/pcan.2012.1

By:

Azzouni, F;
Mohler, J

Publication type:

Article

Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 250, doi. 10.1038/pcan.2012.9

By:

Mani, J;
Vallo, S;
Barth, K;
Makarević, J;
Juengel, E;
Bartsch, G;
Wiesner, C;
Haferkamp, A;
Blaheta, R A

Publication type:

Article

Role of denosumab in prostate cancer.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 231, doi. 10.1038/pcan.2012.2

By:

Helo, S;
Manger, J P;
Krupski, T L

Publication type:

Article

Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 308, doi. 10.1038/pcan.2012.18

By:

Egerdie, R B;
Saad, F;
Smith, M R;
Tammela, T L J;
Heracek, J;
Sieber, P;
Ke, C;
Leder, B;
Dansey, R;
Goessl, C

Publication type:

Article

Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 256, doi. 10.1038/pcan.2012.10

By:

Blana, A;
Robertson, C N;
Brown, S C W;
Chaussy, C;
Crouzet, S;
Gelet, A;
Conti, G N;
Ganzer, R;
Pasticier, G;
Thuroff, S;
Ward, J F

Publication type:

Article

A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 283, doi. 10.1038/pcan.2012.4

By:

Marcus, D M;
Goodman, M;
Jani, A B;
Osunkoya, A O;
Rossi, P J

Publication type:

Article

Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 237, doi. 10.1038/pcan.2011.71

By:

Sevilla, C;
Maliski, S L;
Kwan, L;
Connor, S E;
Litwin, M S

Publication type:

Article

Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 296, doi. 10.1038/pcan.2012.12

By:

Tunn, U W;
Canepa, G;
Kochanowsky, A;
Kienle, E

Publication type:

Article

Targeted therapy with fatty acid synthase inhibitors in a human prostate carcinoma LNCaP/tk-luc-bearing animal model.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 260, doi. 10.1038/pcan.2012.15

By:

Chen, H-W;
Chang, Y-F;
Chuang, H-Y;
Tai, W-T;
Hwang, J-J

Publication type:

Article

The prevalence of lower urinary tract symptoms and treatment-seeking behaviour in males over 40 years in Singapore: a community-based study.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 273, doi. 10.1038/pcan.2011.69

By:

Chong, C;
Fong, L;
Lai, R;
Lau, W K O;
Hartmann, M;
Chia, S E

Publication type:

Article

MTHFR polymorphism and the risk of prostate cancer: a meta-analysis of case-control studies.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 244, doi. 10.1038/pcan.2012.5

By:

Li, X-L;
Xu, J-H

Publication type:

Article

Body mass index and risk of BPH: a meta-analysis.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 265, doi. 10.1038/pcan.2011.65

By:

Wang, S;
Mao, Q;
Lin, Y;
Wu, J;
Wang, X;
Zheng, X;
Xie, L

Publication type:

Article

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 303, doi. 10.1038/pcan.2012.13

By:

Kellokumpu-Lehtinen, P-L;
Hjälm-Eriksson, M;
Thellenberg-Karlsson, C;
Åström, L;
Franzen, L;
Marttila, T;
Seke, M;
Taalikka, M;
Ginman, C

Publication type:

Article

Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy.

Published in:

Prostate Cancer & Prostatic Diseases, 2012, v. 15, n. 3, p. 278, doi. 10.1038/pcan.2011.70

By:

Dittrich, R;
Kurth, J;
Decelle, E A;
DeFeo, E M;
Taupitz, M;
Wu, S;
Wu, C-l;
McDougal, W S;
Cheng, L L

Publication type:

Article